Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chemistry

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,699 result(s) found for: Chemistry. Displaying page 74 of 85.
    «« First « Previous 70  71  72  73  74  75  76  77  78  Next» Last»»
    EudraCT Number: 2013-001037-40 Sponsor Protocol Number: IFX-1-P2.1 Start Date*: 2014-02-11
    Sponsor Name:InflaRx GmbH
    Full Title: A phase II randomized, placebo-controlled, double-blind, dose controlled trial in patients suffering from early, newly developing abdominal or pulmonary derived septic organ dysfunction to evaluate...
    Medical condition: septic organ dysfunction
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000756-41 Sponsor Protocol Number: DEB-EPIV-201 Start Date*: 2006-04-24
    Sponsor Name:Debiopharm SA
    Full Title: Phase IIa Multicenter 1 Week Treatment, Randomised, Double-Blind, Placebo Controlled Study of Depelestat in Patients Suffering from Acute Respiratory Distress Syndrome
    Medical condition: Acute Respiratory Distress Syndrome (ARDS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000346-30 Sponsor Protocol Number: CINC424XDE04T Start Date*: 2015-03-16
    Sponsor Name:Universität Leipzig
    Full Title: An open-label, multicenter study of INC424 monotherapy or in combination with azacitidine for patients with post-myeloproliferative disorders (MPD) – AML or with CMML
    Medical condition: Chronic Myelomonocytic Leukemia and secondary Acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10054350 Chronic myelomonocytic leukemia LLT
    20.0 100000004864 10028557 Myeloid leukemia, acute LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003257-15 Sponsor Protocol Number: A083-02 Start Date*: 2018-04-12
    Sponsor Name:Acceleron Pharma Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy
    Medical condition: Facioscapulohumeral Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10064087 Facioscapulohumeral muscular dystrophy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003402-46 Sponsor Protocol Number: CAN04CLIN005 Start Date*: 2021-09-23
    Sponsor Name:Cantargia AB
    Full Title: A randomized non-comparative open-label phase 1b/2 study of nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. “TRIFOUR study”.
    Medical condition: Unresectable locally advanced or metastatic triple negative breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10084066 Triple negative breast cancer metastatic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004214-14 Sponsor Protocol Number: P311-201 Start Date*: 2016-10-13
    Sponsor Name:Upsher-Smith Laboratories, Inc.
    Full Title: A Phase 1/2 Dose-escalation of USL311 as Single Agent and in Combination with Lomustine (CCNU) in Subjects with Advanced Solid Tumors, with Subsequent Single Agent and Combination Phase 2 Cohorts f...
    Medical condition: Advanced Solid Tumors/Relapsed/Recurrent Glioblastoma Multiforme (GBM)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000516-37 Sponsor Protocol Number: TS-020DESE Start Date*: 2021-03-04
    Sponsor Name:TurnSole Biologics Llc
    Full Title: A Phase I/II open-label study for Azacitidine, initiated with a lead-in dose escalation pharmacokinetic Phase I/b part in the 20–50 mg/m2 range to evaluate safety in Hospitalized COVID-19 Patients ...
    Medical condition: COVID-19 patients with confirmed sever viral infection of SARS-COV-2
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10047461 Viral infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002766-21 Sponsor Protocol Number: 1199.33 Start Date*: 2012-05-02
    Sponsor Name:Boehringer Ingelheim Hellas
    Full Title: An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF)
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) PT (Completed) BE (Completed) ES (Completed) DE (Completed) FI (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000373-80 Sponsor Protocol Number: DERM-101 Start Date*: 2018-05-24
    Sponsor Name:Dermecular Therapeutics, Inc.
    Full Title: A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier’s Disease or H...
    Medical condition: Darier’s Disease or Hailey-Hailey Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10011860 Darier's disease LLT
    20.1 100000004850 10019029 Hailey-Hailey disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002348-99 Sponsor Protocol Number: AUTH88622 Start Date*: 2014-09-22
    Sponsor Name:Aristotle University Thessaloniki
    Full Title: A randomised, double blind, placebo-controlled study of the effect of liraglutide on arterial blood pressure in hypertensive patients with type 2 diabetes mellitus
    Medical condition: Hypertention, Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    17.0 10047065 - Vascular disorders 10020772 Hypertension PT
    17.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003696-30 Sponsor Protocol Number: 201928 Start Date*: 2016-03-11
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomised, double-blind, placebo-controlled study to evaluate the safety, efficacy and changes in induced sputum and blood biomarkers following daily repeat doses of inhaled GSK2269557 for 12 we...
    Medical condition: COPD
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    20.0 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-003396-18 Sponsor Protocol Number: TMC114FD2HTX1007 Start Date*: 2020-12-23
    Sponsor Name:Janssen Sciences Ireland UC
    Full Title: A Single-Dose, Open-Label, Randomized, Replicate Crossover Pivotal Bioequivalence Study in Healthy Adult Participants to Assess the Bioequivalence of Darunavir 675 mg, Emtricitabine 200 mg, and Ten...
    Medical condition: Healthy Volunteers; Human immunodeficiency virus type 1 (HIV-1)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005212-14 Sponsor Protocol Number: 200812 Start Date*: 2016-04-20
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A phase IIIB, 24-week randomised, double-blind study to compare 'closed' triple therapy (FF/UMEC/VI) with 'open' triple therapy (FF/VI + UMEC), in subjects with chronic obstructive pulmonary diseas...
    Medical condition: in subjects with chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) RO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001810-16 Sponsor Protocol Number: 62024 Start Date*: 2004-11-25
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versu...
    Medical condition: Gastrointestinal stromal tumors (GIST) are mesenchymal neoplasms usually arising from the gastrointestinal wall. Pathologically,they present with spindle cells in most cases. Immunohistochemically...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051066 Gastrointestinal stromal tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003796-17 Sponsor Protocol Number: CST103/CST139-CLIN-010 Start Date*: 2020-10-22
    Sponsor Name:CuraSen Therapeutics, Inc.
    Full Title: An Open-Label Brain Imaging and Cognition Study to Determine Changes in Cerebral Perfusion and Cognition After Oral Administration of CST-103 or CST-139
    Medical condition: Patients with Mild Cognitive Impairment or Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10009846 Cognitive impairment LLT
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-004438-40 Sponsor Protocol Number: GI1950 Start Date*: 2020-04-06
    Sponsor Name:Department of Oncology, Herlev & Gentofte Hospital
    Full Title: Phase 2 study in pretreated patients with advanced pancreatic cancer to assess efficacy of ipilimumab, nivolumab and tocilizumab in combination with radiation.
    Medical condition: Pretreated patients with advanced pancreatic cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    21.0 100000004864 10033607 Pancreatic cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000127-12 Sponsor Protocol Number: TM006 Start Date*: 2022-01-03
    Sponsor Name:Saniona A/S
    Full Title: A Phase 2b, Double-blind, Randomized, Placebo-controlled, Multi center, 16-week Dose finding, Safety and Efficacy Study with Open-label Extension Period of Tesomet in Adult and Adolescent Subjects ...
    Medical condition: Prader-Willi Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001337-40 Sponsor Protocol Number: BXCL501-105 Start Date*: 2021-10-05
    Sponsor Name:BioXcel Therapeutics, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER
    Medical condition: Subject that meets DSM-5 criteria for schizophrenia, schizoaffective, or schizophreniform disorder, or other specified/unspecified schizophrenia spectrum and/or other psychotic disorders OR Subjec...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    20.0 10037175 - Psychiatric disorders 10039629 Schizophrenia childhood LLT
    21.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2020-005576-35 Sponsor Protocol Number: CP-PRO-CoVLP-021 Start Date*: 2021-05-06
    Sponsor Name:Medicago R&D Inc.
    Full Title: A Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years o...
    Medical condition: Covid-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000931-35 Sponsor Protocol Number: D6470C00005 Start Date*: 2020-10-05
    Sponsor Name:AstraZeneca AB, 151 85 Södertälje, Sweden
    Full Title: A Phase 2a Randomised, Double Blind, Multi-centre Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults with Type 2 Diabetes
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 70  71  72  73  74  75  76  77  78  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 04 18:01:48 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA